DRUG NAME

ESTRAMUSTINE :

SYNONYM(S): Estramustine sodium phosphate

COMMON TRADE NAME(S): EMCYT(r), ESTRACYT(r)

CLASSIFICATION

Alkylating agent :

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

MECHANISM OF ACTION

[1] :

Estramustine phosphate is a combination of estradiol with nornitrogen mustard. The precise mechanism of action of estramustine is unknown. Unlike other alkylating agents, estramustine does not directly damage DNA.

PHARMACOKINETICS

[2,3,4,5] :

Oral Absorption 75% absorbed, rate and extent of absorption decreased when taken with milk, food or calcium-rich drugs
Distribution appears to concentrate in prostatic tissue
cross blood brain barrier? no information found
Vd no information found
PPB no information found
Metabolism dephosphorylated in intestines and plasma, then oxidized in liver
active metabolite(s) estramustine, estromustine
inactive metabolite(s) yes
Excretion urine and feces
feces 14-21% in 7 days
urine 22-36% in 2-8 days
t1/2 20 hours
Cl no information found

USES

[6] :

Prostate cancer

No pediatric indications.

Health Protection Branch approved indication.

Cancer Drug Manual September 1994

Estramustine

SPECIAL PRECAUTIONS

[6,7] :

Contraindicated

in patients with severe hepatic or cardiac disease, or active thrombophlebitis or thromboembolic disorders.

Low-dose breast radiation

prior to treatment may prevent gynecomastia in male patients.

Estramustine is potentially mutagenic and carcinogenic. Patients should be advised to use birth control if their partner is of child-bearing age. Breast feeding is not recommended due to the potential secretion into breast milk and because it interferes with milk volume and content.

SIDE EFFECTS

[6,8] :

ORGAN SITE SIDE EFFECT ONSET
cardiovascular congestive heart failure (rare) D
thromboembolism D
sodium retention, edema D
dermatologic skin rash (rare) E
endocrine impotence and decreased libido (20-50%) E
gynecomastia L
gastrointestinal nausea (transient) I
vomiting (occasional) I
diarrhea (rare) E
hematologic myelosuppression (uncommon) E
hepatic elevated liver function tests E
renal/metabolic decreased glucose tolerance D

Dose-limiting side effects are underlined.

I = immediate (onset in hours to days); E = early (days to weeks); D = delayed (weeks to months); L = late (months to years)

INTERACTIONS

[6] :

AGENT EFFECT MECHANISM MANAGEMENT
milk, milk products or calcium-containing drugs (eg, calcium supplements, some antacids) decreased effect of estramustine impaired absorption of estramustine do not take simultaneously with estramustine

Cancer Drug Manual September 1994

SUPPLY AND STORAGE:

[6,9]

Capsules: Estramustine sodium phosphate 140 mg; store in the refrigerator (2-8o C); keep bottle tightly closed. Bisulfite-, gluten-, lactose- and tartrazine-free.

DOSAGE GUIDELINES

[2,3,4] :

Refer to protocol by which patient is being treated.

Oral:

daily: 14 mg/kg/day (ie, one 140 mg capsule for each 10 kg) in 3-4 divided doses

range: 10-16 mg/kg/day

Capsules should be taken on an empty stomach (1 hour before or 2 hours after a meal).

Adequate trial:

30 days

Dosage in myelosuppression: administer with caution, no details found Dosage in renal failure: no adjustment required Dosage in hepatic failure: administer with caution, no details found

Cancer Drug Manual September 1994

Estramustine

ESTRAMUSTINE FACT SHEET

FOR THE HEALTH CARE PROFESSIONAL

OTHER NAMES estramustine sodium phosphate, EMCYT(r), ESTRACYT(r)
USES * HPB approved prostate cancer *
DOSAGE FORMS oral capsule: 140 mg (refrigerate)
USUAL DOSE RANGE oral: 10-16 mg/kg/day po in 3-4 divided doses on an empty stomach
DOSE REDUCTIONS severe uncontrolled nausea and vomiting
ONSET SIDE EFFECT * may be life-threatening side effects in bold, italic type are common
IMMEDIATE (hours to days) nausea and vomiting (20-50%)
EARLY (days to weeks) impotence or decreased sex drive (decreased libido) diarrhea (20-50%) elevated liver function tests low WBC (myelosuppression) skin rash (rare)
DELAYED/LATE (weeks to years) breast swelling or tenderness (gynecomastia, 20-50%) fluid retention (edema) congestive heart failure (secondary to edema) stroke loss of diabetic control (decreased glucose tolerance)
CONTRAINDICATIONS severe liver (hepatic) or heart (cardiac) disease blood clots (thromboembolic disorders) known hypersensitivity to either estradiol or mechlorethamine
SIGNIFICANT INTERACTIONS calcium (milk and milk products, calcium supplements, calcium-containing antacids, etc.)
LABORATORY MONITORING monthly: CBC, liver function tests, kidney function tests.

TEACHING AIDS * For the Patient: Estramustine

NOTES:

* Give estramustine with a glass of water on an empty stomach, either 1 hour before or 2 hours after eating.

Cancer Drug Manual September 1994

FOR THE PATIENT

Estramustine : Other names: estramustine sodium phosphate, EMCYT(r), ESTRACYT(r)

SIDE EFFECTS MANAGEMENT
Nausea and vomiting may occur. *Drink plenty of fluids. *Eat often in small amounts. *Try the ideas in For the Patient: Nausea .
Breast swelling or soreness often occurs. This may return to normal when you stop taking estramustine.

Cancer Drug Manual September 1994

Estramustine

SIDE EFFECTS MANAGEMENT
Diarrhea may occur. *Drink plenty of fluids. *Eat often in small amounts. *Eat low fibre foods such as rice, white bread and cooked vegetables. *Avoid high fibre foods such as bran, whole grain breads and cereals, nuts, raw fruits and raw vegetables.
Loss of libido (sex drive) often occurs. This may return to normal when you stop taking estramustine.
Swelling of hands, feet or lower legs may occur if your body retains extra fluid. *Elevate your feet when sitting. *Avoid tight clothing.
Sugar control may be affected in diabetics. *Check your blood or urine sugar regularly if you are diabetic.

STOP TAKING YOUR ESTRAMUSTINE AND SEE YOUR DOCTOR OR GET EMERGENCY HELP IMMEDIATELY IF YOU HAVE:

SEE YOUR DOCTOR AS SOON AS POSSIBLE (DURING OFFICE HOURS) IF YOU HAVE:

Skin rash. Signs of anemia such as unusual tiredness or weakness.

CHECK WITH YOUR DOCTOR IF ANY OF THE FOLLOWING CONTINUE OR BOTHER YOU:

Uncontrolled nausea, vomiting, or diarrhea. For diabetics; uncontrolled blood sugars. Excessive breast swelling or soreness. Swelling of hands, feet or lower legs.

REPORT ADDITIONAL PROBLEMS TO YOUR DOCTOR.

See Chemotherapy and You: a Guide to Self-help During Treatment available free from the Canadian Cancer Society for more information on managing side effects.

Cancer Drug Manual September 1994

BIBLIOGRAPHY:

  1. Haskell CM, ed. Cancer treatment, 3rd ed. Philadelphia: WB Saunders Co, 1990:101-2.

  2. Dorr RT, Fritz WL eds. Cancer chemotherapy handbook. New York: Elsevier Science Publishing Co Inc, 1980:407-9.

  3. Reynolds JEF, ed. Martindale: The extra pharmacopoeia, 28th ed. London: Pharmaceutical Press, 1982:208.

  4. Knoben JE, Anderson PO, eds. Handbook of clinical drug data, 6th ed. Hamilton: Drug Intelligence Publications Inc, 1988:408.

  5. Gunnarsson PO, Davidsson T, Andersson SB, et al. Impairment of estramustine phosphate by concurrent intake of milk and food. European J Clin Pharmacol 1990; 38:189-93.

  6. Krogh CME, ed. Compendium of pharmaceuticals and specialties, 27th ed. Ottawa: Canadian Pharmaceutical Association, 1992:378.

  7. BCCA GUEMCYT protocol: Estramustine phosphate for androgen independent prostate cancer, 17 Jul 93.

  8. USP DI Volume I: Drug information for the health care professional, 13th ed. Rockville: United States Pharmacopeial Convention Inc, 1993:1330-2.

  9. Pharmacia (Canada) Inc. Emcyt bottle label. Baie D'Urfe, Quebec.

  10. USP DI Volume II: Advice for the patient: drug information in lay language, 13th ed. Rockville: United States Pharmacopeial Convention Inc, 1993:578-80.

  11. Benson RC, Hartley-Asp. Mechanism of action and clinical uses of estramustine. Cancer Invest 1990; 8:375-80.

  12. Benson RC, Gill GM. Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 1986; 9:341-51.

  13. Benson RC, Wear JB, Gill GM. Treatment of Stage D hormone resistant cancer of the prostate with estramustine phosphate. J Urol 1979; 121:452-4.

Cancer Drug Manual September 1994